Journal
MOLECULAR CANCER RESEARCH
Volume 7, Issue 4, Pages 592-600Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-08-0316
Keywords
-
Categories
Funding
- NIH [P30-CA 16672, POI-CA0099031, IRO1-CA109570, IRO1CA119127, P50 CA116199]
Ask authors/readers for more resources
Overexpression of the ErbB2 receptor tyrosine kinase is prevalent in similar to 30% of human breast cancers and confers Taxol resistance. Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1). However, the mechanism of ErbB2-mediated p21(Cip1) up-regulation is unclear. Here, we show that ErbB2 up-regulates p21(Cip1) transcription through increased Src activity in ErbB2-overexpressing cells. Src activation further activated signal transducer and activator of transcription 3 (STAT3) that recognizes a SIE binding site on the p21(Cip1) promoter required for ErbB2-mediated p21(Cip1) transcriptional up-regulation. Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells. Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells. Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers. (Mol Cancer Res 2009;7(4):592-600)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available